 - MM refractory to previous treatment with one or more glucocorticoids, parenteral PI i.e., bortezomib andor carfilzomib, IMiD i.e., lenalidomide andor pomalidomide, and the anti-CD38 mAb, daratumumab. Refractory is defined as 25 response to therapy, or progression during therapy or progression within 60 days after completion of therapy. 